Figure 2. NKp30-Ig treatment reduces growth of prostate cell line DU145 in vivo.

Male nude mice injected with the human prostate tumor line DU145 (4×10⁶), were treated with NKp30-Ig (n = 10), NKp46D2-Ig (n = 9), control human IgG1 (n = 10), or PBS (n = 10). Day 1 is defined at two weeks post-injection when tumors became visible. Treatments were administered 5 times (days 1, 7, 15, 25 and 34, marked by arrows) and included an initial larger dose of the proteins (20 mg/kg) followed by lower doses (10 mg/kg). Tumor progression was evaluated every three days by measuring the diameter of the tumors. The graphs show the average diameter (mm) of the tumors in each group measured in days 1–45.